TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
Stocks · News reference
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
Shares of semiconductor and chip companies are trading higher. The broader industry may be rallying alongside memory and storage-related peers.
Cerebras Systems Stock Climbs Wednesday: What's Going On?
Shares of Cerebras Systems are rebounding Wednesday morning, recovering Tuesday's losses as traders absorb a 14.6 million share post-IPO lockup expiration alongside new international data center momentum.
Shares of semiconductor companies are trading lower as inflation concerns and elevated oil prices push U.S. and global bond yields higher, raising concerns that the Federal Reserve could tighten monetary policy later this month. Higher rates can weigh on growth stocks by making future profits less attractive.
Cerebras Signs Seven-Year Finland Data Center Deal. Stock Falls Anyway
Cerebras is developing a 165-MW AI data center in Mikkeli, Finland, expanding its infrastructure footprint to support growing AI compute demand.